Cardiff Oncology appoints interim CEO as executives step down

Cardiff Oncology Inc. (NASDAQ: CRDF) announced leadership changes as the clinical-stage biotechnology company transitions toward late-stage development of its cancer therapies.

Mani Mohindru, who has served on Cardiff's board since 2021, was appointed interim chief executive officer effective immediately. Mark Erlander, the outgoing CEO, and James Levine, chief financial officer, have stepped down from their positions.

Brigitte Lindsay was promoted to chief accounting officer from her previous role as senior vice president of finance. Lindsay has been with the company for more than 14 years. Cardiff has initiated searches for permanent CEO and CFO positions.

The company's lead product candidate, onvansertib, is an oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer. The drug is also being evaluated in investigator-initiated studies for metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia.

"As Cardiff Oncology prepares for the next stage of clinical and corporate development, the Board concluded that this was the right moment to align executive and financial leadership with the Company's evolving needs," said Rodney S. Markin, chairman of the board.

Mohindru is founder of Roshon Therapeutics and serves on the board of CytomX Therapeutics Inc. (NASDAQ: CTMX). She previously served as CEO of Novasenta and CereXis, and held senior positions at Cara Therapeutics Inc. and Curis Inc. She also worked as an equity research analyst covering biotechnology at UBS, Credit Suisse, and ThinkEquity.

The executive changes reflect Cardiff's focus on advancing its clinical programs as they mature toward late-stage development, according to the company's statement.

You May Also Be Interested In

• Celcuity prices $500 million convertible notes offering
• Expro extends Gulf of America contract with Solus technology deployment
• FDA grants fast track status to Verastem's lung cancer drug VS-7375